METABOLIC DISORDERS IN PATIENTS OPERATED FOR PANCREATIC CANCER

Authors

  • D. TIMOFTE University of Medicine and Pharmacy “Grigore T. Popa”-Iasi
  • Roxana LIVADARIU University of Medicine and Pharmacy “Grigore T. Popa”-Iasi
  • V. BINTINTAN University Hospital - Cluj-Napoca
  • C. DIACONU University of Medicine and Pharmacy “Grigore T. Popa”-Iasi
  • Lidia IONESCU University of Medicine and Pharmacy “Grigore T. Popa”-Iasi
  • A. A. SANDBERG Karolinska Huddinge Institute - Stockholm, Sweden
  • D. C. MARICIUC University of Medicine and Pharmacy “Grigore T. Popa”-Iasi
  • R. DANILA University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

Abstract

Adenocarcinoma of the pancreas presents a major threat with a 5-years survival rate of 5%. Whipple pancreaticoduodenectomy (PD) is the standard procedure for cephalopancreatic neoplasm. After an extended resection and reconstruction of superior gastrointestinal tract the digestive physiology might be heavily disrupted. A literature review of metabolic alterations of patients who suffered a major pancreatic resection is performed, regarding micronutrients, lipid absorption and pancreatogenic diabetes. Long-term survivors following PD generally have a satisfactory nutritional status although with subclinical iron, vitamin D and selenium deficiency. These patients should be followed-up also regarding these micronutrients and properly dietary supplemented when necessary, also considering the increased life expectancy. Approximately 17-25% of patients will develop insulin-dependent diabetes but pancreatogenic diabetics have elevated levels of serum insulin and minimal or absent response to food intake, as opposed to a type I diabetics, where insulin serum is normal or elevated and there is an exaggerated response to ingestion of sugar.

Author Biographies

  • D. TIMOFTE, University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

    Faculty of Medicine                                                                                                                                                          Department of IIIrd Surgery

  • Roxana LIVADARIU, University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

    Faculty of Medicine                                                                                                                                                    Department of IIIrd Surgery
    Ph.D. student

  • V. BINTINTAN, University Hospital - Cluj-Napoca

    Department of Ist Surgery

  • C. DIACONU, University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

    Faculty of Medicine                                                                                                                                                      Department of IIIrd Surgery

  • Lidia IONESCU, University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

    Faculty of Medicine                                                                                                                                                      Department of IIIrd Surgery

  • A. A. SANDBERG, Karolinska Huddinge Institute - Stockholm, Sweden

    Department of Upper Gastrointestinal Surgery

  • D. C. MARICIUC, University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

    Faculty of Medicine                                                                                                                                                          Department of IIIrd Surgery

  • R. DANILA, University of Medicine and Pharmacy “Grigore T. Popa”-Iasi

    Faculty of Medicine                                                                                                                                                    Department of IIIrd Surgery

References

1. Beger HG, et al. Treatment of pancreatic cancer: challenge of the facts. World J Surg 2003; 27(10): 1075-1084.
2. Kleeff J, et al. Pancreatic cancer: from bench to 5-year survival. Pancreas 2006; 33(2): 111-118.
3. Tamm EP, et al. Diagnosis, staging, and surveillance of pancreatic cancer. Am J Roentgenol 2003; 180(5): 1311-1323.
4. Cameron JL et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244(1): 10-15.
5. Saif MW. Advancements in the management of pancreatic cancer: 2013.JOP. 2013 Mar 10;14(2):112-118.
6. Melvin WS, et al. Outcome analysis of long-term survivors following pancreaticoduodenectomy. J Gastrointest Surg 1998; 2(1): 72-78.
7. McLeod RS, et al. Quality of life, nutritional status and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 1995; 169(1): 179-185.
8. Van Berge Henegouwen MI, et al. Postoperative weight gain after standard Whipple's procedure versus pylorus-preserving pancreatoduodenectomy: the influence of tumour status. Br J Surg 1998; 85(7): 922-926.
9. Gröber U. Antioxidants and other micronutrients in complementary oncology. Breast Care (Basel) 2009; 4(1): 13–20.
10. Armstrong T, Ruiz-Jasbon F, Shek FW, Permert J, Johnson CD. Pancreatico¬duodenectomy for peri-ampullary neoplasia leads to specific micronutrient deficiencies. Pancreatology 2007; 7(1):37-44.
11. Layer P, Holtmann G. Pancreatic enzymes in chronic pancreatitis. Int J Pancreatol 1994; 15(1): 1-11.
12. Morrow CE, et al. Chronic pancreatitis: long-term surgical results of pancreatic duct drainage, pancreatic resection, and near-total pancreatectomy and islet autotransplantation. Surgery 1984; 96(4): 608-616.
13. Beger HG, Buchler M. Duodenum-preserving resection of the head of the pancreas in chronic pancre-atitis with inflammatory mass in the head. World J Surg 1990; 14(1): 83-87.
14. Traverso LW, Kozarek RA. Pancreatoduodenectomy for chronic pancreatitis: anatomic selection criteria and subsequent long-term outcome analysis. Ann Surg 1997; 226(4): 429-435.
15. Andren-Sandberg A, Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983; 198(5): 605-610.
16. Karmann HF, Laurent M and Mialhe P. Pancreatic hormones disappearance after total pancreatectomy in the duck: correlation between plasma glucagon and glucose. Horm Metab Res 1987; 19(11): 538-541.
17. Unger RH. Glucagon physiology and pathophysiology. N Engl J Med 1971; 285(8): 443-449.
18. Slezak LA and Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg 2001; 25(4): 452-460.
19. Frey CF, Child CG and Fry W. Pancreatectomy for chronic pancreatitis. Ann Surg 1976; 184(4): 403-413.
20. Dresler, C.M., Fortner, J.G., McDermott, K., Bajorunas, D.R. - Metabolic consequences of (regional) total pancreatectomy. Ann. Surg 1991; 214: 131.
21. Sugiyama M, Atomi Y. Pylorus-preserving total pancreatectomy for pancreatic cancer. World J Surg. 2000; 24: 66–70.
22. Jethwa P, Sodergren M, Lala A, Webber J, Buckels JA, Bramhall SR, et al. Diabetic control after total pancreatectomy. Dig Liver Dis 2006; 38: 415–419.
23. Muller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007; 246: 966–974.
24. Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg 2005; 9: 1059–1066.
25. Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and post-operative sequelae. J Gastrointest Surg 2007; 11: 209–216.
26. Stauffer, J. A., Nguyen, J. H., Heckman, M. G., Grewal, M. S., Dougherty, M., Gill, K. R. S., Jamil, L. H., Scimeca, D., Raimondo, M., Smith, C. D., Martin, J. K. and Asbun, H. J. Patient outcomes after total pancreatectomy: a single centre contemporary experience. HPB 2009; 11: 483–492.

Additional Files

Published

2018-05-07